Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Matthew Cooperberg presented data from PROCEED, an ongoing Phase 4 registry of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (ST). ST is an immunotherapy that targets prostatic acid phosphatase. While PROCEED is ongoing, baseline demographics and treatment practice patterns were reported. Data from approximately 1 400 patients was included. The majority of patients were Caucasian (87.6%) with a median age of 72 years. Median baseline PSA was 16.1 ng/mL, and 49.9% of patients had Gleason ≥ 8 disease.

auaClose to three-quarters of patients underwent local therapy, the majority with radiation (56.9%) or radical prostatectomy (35.8%). Fifteen percent of patients received prior chemotherapy (12.4% docetaxel). Patients treated in oncology practices more commonly received prior oral anti-androgen (67%) and chemotherapy (19%) compared to patients treated in urology practices (41.7% and 5.9%, respectively). The preliminary data from PROCEED provides a window into current treatment patterns for mCRPC. Dr. Cooperberg concluded that PROCEED will continue to provide useful information for tracking practice patterns and care trends for men with mCRPC prior and subsequent to treatment with ST.

Click HERE to view the poster from this session

Presented by Matthew Cooperberg, MD, MPH at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

University of California, San Francisco USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting